CD274 Molecule Peptide 1
Rabbit Monoclonal Antibody
Peptide, Recombinant Full-length, Endogenous
This PDF contains the evaluation results provided by the Human Protein Atlas (www.proteinatlas.org)
Tissue Micro-Array(TMA) core of lung cancer showing cytoplasmic staining using Antibody CPTC-CD274-1. Titer: 1:1000
Immunofluorescence staining of human cell lines Jurkat, MCF7 and NCI H226 with CPTC-CD274-1 Ab shows no localization of CD274 protein.
Protein Array in which CPTC-CD274-1 is screened against the NCI60 cell line panel for expression. Data is normalized to a mean signal of 1.0 and standard deviation of 0.5.
Automated western blot using CPTC-CD274-1 as primary antibody against buffy coat (lane 2), HeLa (lane 3), Jurkat (lane 4), A549 (lane 5), MCF7 (lane 6), and H226 (lane 7) cell lysates. Expected molecular weight - 26.33 kDa. Molecular weight standards are also included (lane 1). Inconclusive data.
Result: Presumed Positive (with additional bands)
Western blot using CPTC-CD274-1 as primary antibody against HeLa (lane 2), Jurkat (lane 3), A549 (lane 4), MCF7 (lane 5) and NCI H226 (lane 6) cell lysates. Expected molecular weight 33.3 kDa, 20.2 kDa, and 20.5 kDa. Molecular weight standards (MW Stds.) are also included (lane 1). Jurkat and MCF-7 are presumed positive. All other cell lines are negative.
Western blot using CPTC-CD274-1 as primary antibody against human PD-L1 / CD274 recombinant protein (lane 2). Expected molecular weight - 26.33 kDa. Molecular weight standards are also included (lane 1).
NCI Identification Number:
CD274 Molecule Peptide 1
CPTC-CD274 Peptide 1
CD274 Molecule; Programmed Cell Death 1 Ligand 1; CD274 Antigen; B7 Homolog 1; PD-L1; B7H1; PDL1; PDCD1 Ligand 1; PDCD1LG1; PDCD1L1; HPD-L1; B7-H1; B7-H; Programmed Death Ligand 1; CD274
This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants. CD274, also commonly referred to as PDL1, is a ligand that binds with the receptor PD1, commonly found on T-cells, and acts to block T-cell activation. PD1 expression has been observed in a variety of cancers including melanoma and non-small cell lung cancer. The interaction of PD1/PDL1 is hypothesized to be a possible mechanism for the tumor to escape immune response. A number of checkpoint blockade inhibitors including pembrolizumab and nivolumab have been developed that target the PD1/PDL1 interaction in order to allow T-cells to recognize tumor cells without being deactivated by the tumor.CD274 (CD274 Molecule) is a Protein Coding gene. Diseases associated with CD274 include Testicular Lymphoma and Smoldering Myeloma. Among its related pathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. An important paralog of this gene is PDCD1LG2.Plays a critical role in induction and maintenance of immune tolerance to self (PubMed:11015443, PubMed:28813417, PubMed:28813410). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443, PubMed:28813417, PubMed:28813410). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survivalThe interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity).
UniProt Accession Number:
Calculated Isoelectric Point:
No SOPs available.
Get it for free at Adobe.com